Shunned by investors, Henlius hangs up on its Hong Kong listing
The Fosun-backed drugmaker’s privatization comes as its stock price has wilted over 60% since its IPO five years ago and it failed to use the listing to raise additional funds…
Akeso marks profit milestone with swift rights issue
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…
FAST NEWS: Henlius expects first-ever annual profit on strong drug sales
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Monday it expects to report a net profit of 500 million yuan ($69.5 million) or more for 2023, reversing a loss of 695 million…
FAST NEWS: Henlius swings to the black on strong sales growth
The latest: Shanghai Henlius Biotech Inc. (2696.HK) on Wednesday reported a net profit of 408 million yuan ($56.2 million) in the first three quarters of this year, reversing a loss of…
Debt pressures cast cloud over Fosun Pharma results
The drugmaker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings Key Takeaways:…
As its stock gets set for upgrade, Boan Biotech still faces two big risks
Listed at the end of 2022, the biopharmaceutical company is about to have a designation reserved for high-risk stocks removed from its ticker Key Takeaways: With two products now generating…
FAST NEWS: Henlius Biotech’s revenue doubles in first quarter
The latest: Shanghai Henlius Biotech Inc. (2696.HK) reported its revenue soared 97.2% to 996 million yuan ($145 million) in the first quarter, according to a business update released on Sunday.…
